Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Oculis announced it will present new biomarker data from its Phase 2 ACUITY trial of Privosegtor at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto on October 21-23, 2026. The presentation will highlight plasma NfL and GFAP biomarker analyses demonstrating neuroprotective potential in acute optic neuritis patients. Privosegtor has received FDA Breakthrough Therapy and EMA PRIME designations, with the company planning registrational trials through its PIONEER program.